COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Other Events

COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Other Events
Item 8.01 Other Events

Story continues below

On September7, 2017, Coherus BioSciences, Inc. (the “Company”) issued a press release regarding the U.S. Patent Trial and Appeal Board’s decision to deny the institution of four Inter Partes Reviews brought by the Company related to AbbVie Inc.’s U.S. Patent 9,085,619, which generally concern the HUMIRA (adalimumab) formulation. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 8.01 Financial Statements and Exhibits.

Exhibit No.

Description

99.1 Press release dated September 7, 2017.


Coherus BioSciences, Inc. Exhibit
EX-99.1 2 d448718dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Coherus BioSciences Provides Update on ‘619 IPR Institution Decision Patent Trial and Appeal Board Denies Institution REDWOOD CITY,…
To view the full exhibit click here

About COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS)

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).

An ad to help with our costs